Your Article Summary
See Latest ArticlesNeoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
British Journal of Cancer, 07/02/09
Vandenput I et al. - In a study to investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV), it was found that use of NACT resulted in a high rate (80%) of optimal IDS for treatment of endometrial cancer with transperitoneal spread.
Methods- Pts with endometrial cancer with transperitoneal spread, as determined by laparoscopy (±pleural effusion), were treated with NACT.
- Efficacy was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST), residual tumour at IDS and histopathological assessment of tumour regression.
- 30 pts (median age: 65 yrs) received 3–4 cycles of NACT (83% paclitaxel/carboplatin).
- Histopathological subtypes were as follows: serous (90%), clear cell (3%), and endometrioid (6%) carcinoma.
- Response according to RECIST was as follows: 2 (7%) complete remission, 20 (67%) partial remission, 6 (20%) stable disease, and 2 (7%) progressive disease (PD).
- Pts with PD were not operated upon.
- 24 pts (80%) had optimal cytoreduction (R 1 cm), of whom 22 (92%) were without residual tumour.
- 4 pts were considered inoperable and were excluded from further analysis.
- Median progression-free survival (PFS) and overall survival (OS) times were 13 and 23 mos, respectively.
- Histopathological features of chemoresponse in both uterus and omentum were related to better PFS and OS.
- Absence of tumour infiltration and necrosis were associated with prognosis.
Related Articles
Pneumonectomy After Neoadjuvant Chemotherapy and Radiation for Advanced-Stage Lung Cancer
Annals of Surgical Oncology, 11/18/09
Relevance Score: 67%
Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication
Medical Oncology, 11/10/09
Relevance Score: 67%
Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases
Annals of Surgical Oncology, 10/28/09
Relevance Score: 67%
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer
The American Journal of Surgery, 10/08/09
Relevance Score: 67%
Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
Anti-Cancer Drugs, 10/16/09
Relevance Score: 66%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
Best Practice & Research: Clinical Rheumatology, 12/07/09
Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients
Cancer Prevention Research, 12/06/09
Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer
BMC Cancer, 12/06/09